Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Financial performance shows increased expenses and net loss, raising concerns. However, the company has a strong cash position and positive milestone revenue. The Q&A reveals challenges in insurance coverage and reimbursement delays, but also highlights broad prescriber feedback and patient support systems. The lack of specific data on patient outcomes and reimbursement timelines adds uncertainty. While there are positive aspects, such as milestone revenue, the overall sentiment is tempered by the challenges and uncertainties, leading to a neutral stock price prediction.
Key Financial Performance
Milestone Revenue $1.5 million in the fourth quarter and full-year of 2025. No revenue comparables in 2024. This revenue reflects the milestone earned under the licensing collaboration agreement with Corxel following FDA approval in the U.S. for CARDAMYST in PSVT.
R&D Expense $5.5 million in Q4 2025 compared to $3.9 million in Q4 2024. Full-year R&D expense was $18.1 million compared to $14.4 million in 2024. The increase was primarily due to higher consulting and outside services costs, partially offset by lower personnel-related costs.
G&A Expense $5.1 million in Q4 2025 compared to $4.0 million in Q4 2024. Full-year G&A expense was $17.3 million compared to $16.7 million in 2024. The increase was primarily driven by higher outside-service costs and higher personnel costs.
Commercial Expense $8.2 million in Q4 2025 compared to $4.4 million in Q4 2024. Full-year commercial expense was $28.3 million compared to $11 million in 2024. This increase primarily reflects additional personnel costs, professional costs, and other operational costs associated with preparation for the launch of CARDAMYST.
Net Loss $17.4 million, or $0.16 per share, in Q4 2025 compared to $12.4 million, or $0.19 per share, in Q4 2024. Full-year net loss was $63.1 million, or $0.75 per share, compared to $41.5 million, or $0.67 per share, in 2024.
Cash, Cash Equivalents, and Short-term Investments $106 million as of December 31, 2025. Additional funds raised post-year-end include $75 million from the sale of royalty interest, $10.9 million from at-the-market offering, and $8 million from warrant exercises, resulting in a pro forma cash figure of approximately $200 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA approval of CARDAMYST: CARDAMYST, an etripamil nasal spray, was approved by the FDA for treating paroxysmal supraventricular tachycardia (PSVT) in adults. It is the first new therapeutic option in 30 years for over 2 million patients with PSVT.
Launch of CARDAMYST: The product was made available in retail pharmacies within 6 weeks of FDA approval, with promotional efforts starting mid-February 2026. Initial feedback from prescribers has been positive, with over 150 prescriptions filled by more than 100 unique prescribers in the first month.
European market expansion: Milestone filed a marketing authorization application (MAA) for etripamil nasal spray (TACHYMIST) in Europe in Q4 2025. The EMA accepted the application in January 2026, with a decision expected in the first half of 2027.
Financial position: Milestone reported a pro forma cash figure of $200 million, providing an operating runway into late 2027. This includes funds from RTW royalty payment, warrant exercises, and ATM program sales.
Sales force deployment: A national sales force of 60 representatives was hired, trained, and deployed within 2 months to target 10,000 providers managing PSVT patients.
Commercial strategy for CARDAMYST: Focused on targeting high-prescribing cardiologists and electrophysiologists, ensuring accessibility and affordability for patients, and engaging with payers to demonstrate the product's value in reducing emergency department visits.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company is awaiting a decision from the European Medicines Agency (EMA) for the marketing authorization application for TACHYMIST, expected in the first half of 2027. Regulatory delays or unfavorable decisions could impact international expansion plans.
Insurance and Reimbursement Challenges: The company is facing issues with contracted coverage for CARDAMYST, leading to delays in prescription fulfillment and access for patients. Insurer controls are blocking or delaying access to the drug despite physician demand.
Early Launch Risks: The company is in the early stages of launching CARDAMYST, and trends or durable patterns in prescription volume and market adoption are not yet established. This creates uncertainty about the product's commercial success.
Financial Risks: The company reported a net loss of $63.1 million for 2025, with increased expenses in R&D, G&A, and commercial operations. While the company has a pro forma cash figure of $200 million, sustained losses could impact long-term financial stability.
Market Adoption Risks: The success of CARDAMYST depends on its adoption by healthcare providers and patients. Early data shows prescriptions are being written, but the lack of contracted coverage and insurer controls could hinder broader adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects prescription volume for CARDAMYST to increase and commercial coverage to expand over time, with more meaningful progress anticipated in the back half of 2026.
Market Trends and Growth Expectations: Milestone Pharmaceuticals anticipates that the PSVT market represents a clearly-defined opportunity within cardiovascular specialty pharma. The company is targeting high-prescribing cardiologists, electrophysiologists, and advanced practice providers who manage PSVT, estimating that 1 million patients will receive treatment for their condition in 2026.
Regulatory Approvals: The company has filed a marketing authorization application (MAA) for etripamil nasal spray (TACHYMIST) in Europe, with a decision expected in the first half of 2027.
Financial Projections: Milestone Pharmaceuticals reports a strengthened balance sheet with a pro forma cash figure of approximately $200 million, providing expected operating runway into late 2027.
Commercial Strategy: The company is focused on driving new-patient starts, achieving commercial coverage, and ensuring patients have a good initial experience with CARDAMYST. The commercialization plan aims to drive early trial and usage, achieve broad coverage, and establish a durable franchise in acute arrhythmia management.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How has feedback been to date between the different prescribers that you're targeting? And where are you seeing the most adoption?
A:Feedback has been broad across cardiology, electrophysiology, and APPs (nurse practitioners and physician assistants). APPs are particularly engaged with patients and are a key group for this product.
Q:What are the leading reasons for coverage denial?
A:The leading reasons for coverage denial include basic block-until-review policies by plans, requiring extra paperwork to confirm patient eligibility for CARDAMYST, such as proof of PSVT, emergency department visits, or other events.
Q:How long is it taking for reimbursement to kick in? And what is Milestone doing to ensure patients get the drug during the delay period?
A:Reimbursement timelines vary, with some scripts filled within days, others within weeks, and some still pending after 4 weeks. Milestone has implemented a Patient Support System, co-pay assistance programs, and electronic systems at pharmacies to assist patients during the delay period.
Q:What can you tell us about manufacturing supply and how that side of the business is looking?
A:The company is well-prepared with supply, utilizing leftover R&D batches and maintaining a routine cadence for future batches.
Q:Do you have any sense of what CARDAMYST is replacing when it is being prescribed?
A:It is too early to identify trends, but examples include patients using it before ablation, as a routine course, or replacing 'pill-in-the-pocket' medications. The drug is expected to be used across a broad range of patients.
Q:Have you heard of any patients having an episode post-having CARDAMYST? And if that has happened, has it worked as anticipated?
A:No specific data on this yet, but social listening indicates excitement and peace of mind among patients having the drug available.
Q:Can you remind us of your contracting strategy for reimbursement?
A:The strategy focuses on driving to coverage, starting with commercial plans and later Medicare. The company aims for open access with Prior Auth to-label and reasonable quantity limits. Commercial coverage is expected to start in 2026, with Medicare coverage anticipated by 2027.
Q:What does good formulary positioning look like for CARDAMYST? And how much rebate pressure should we expect as you push for broader access?
A:Good formulary positioning includes open access with Prior Auth to-label and reasonable quantity limits. Rebate pressure is expected to be standard pay-to-play discounts.
Q:What is the patient mix in terms of coverage (commercial vs. Medicare)?
A:The patient mix is roughly 50% commercial (under 65) and 50% Medicare (over 65).
Q:Review of Unclear Management Responses
A:Management avoided providing specific data on how long reimbursement takes, as they stated it is too early to determine trends. They also did not provide detailed feedback on patient outcomes post-CARDAMYST usage, relying instead on anecdotal social listening insights.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CARDAMYST patient
Chief
Corporate
FDA approval
Milestone Pharmaceuticals
Officer
PSVT
achievement
approval CARDAMYST
assistance
authorization
cash
conference
coverage
demand
detail
end
etripamil nasal
expense increase
investment
launch CARDAMYST
market
month launch
payer
prescribers
prescription
program
provider
reimbursement support
sale force
share
statement
treatment
week
MIST Transcript
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals several concerns: low revenue, increased commercial expenses, and a significant net loss. Despite positive elements like reduced R&D and G&A expenses, and an Express Scripts agreement, the Q&A highlights uncertainties, especially regarding prescription volume and payer coverage. The lack of clear guidance on free drug distribution and payer expansion further clouds the outlook. Overall, the financial strain and ambiguous responses suggest a negative sentiment, likely impacting the stock price negatively in the short term.
Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript
Unknown3-20
The earnings call presents a mixed picture. Financial performance shows increased expenses and net loss, raising concerns. However, the company has a strong cash position and positive milestone revenue. The Q&A reveals challenges in insurance coverage and reimbursement delays, but also highlights broad prescriber feedback and patient support systems. The lack of specific data on patient outcomes and reimbursement timelines adds uncertainty. While there are positive aspects, such as milestone revenue, the overall sentiment is tempered by the challenges and uncertainties, leading to a neutral stock price prediction.
MIST Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
